IRIS Accounts Production v25.1.4.42 06757413 director 1.12.23 30.11.24 30.11.24 false true false false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh067574132023-11-30067574132024-11-30067574132023-12-012024-11-30067574132022-11-30067574132022-12-012023-11-30067574132023-11-3006757413ns15:EnglandWales2023-12-012024-11-3006757413ns14:PoundSterling2023-12-012024-11-3006757413ns10:Director12023-12-012024-11-3006757413ns10:PrivateLimitedCompanyLtd2023-12-012024-11-3006757413ns10:SmallEntities2023-12-012024-11-3006757413ns10:AuditExempt-NoAccountantsReport2023-12-012024-11-3006757413ns10:SmallCompaniesRegimeForDirectorsReport2023-12-012024-11-3006757413ns10:SmallCompaniesRegimeForAccounts2023-12-012024-11-3006757413ns10:FullAccounts2023-12-012024-11-300675741312023-12-012024-11-3006757413ns10:RegisteredOffice2023-12-012024-11-3006757413ns5:CurrentFinancialInstruments2024-11-3006757413ns5:CurrentFinancialInstruments2023-11-3006757413ns5:Non-currentFinancialInstruments2024-11-3006757413ns5:Non-currentFinancialInstruments2023-11-3006757413ns5:ShareCapital2024-11-3006757413ns5:ShareCapital2023-11-3006757413ns5:RetainedEarningsAccumulatedLosses2024-11-3006757413ns5:RetainedEarningsAccumulatedLosses2023-11-3006757413ns5:NetGoodwill2023-12-012024-11-3006757413ns5:LandBuildingsns5:ShortLeaseholdAssets2023-12-012024-11-3006757413ns5:FurnitureFittings2023-12-012024-11-3006757413ns5:MotorVehicles2023-12-012024-11-3006757413ns5:ComputerEquipment2023-12-012024-11-3006757413ns5:NetGoodwill2023-11-3006757413ns5:NetGoodwill2024-11-3006757413ns5:NetGoodwill2023-11-3006757413ns5:LandBuildingsns5:ShortLeaseholdAssets2023-11-3006757413ns5:FurnitureFittings2023-11-3006757413ns5:MotorVehicles2023-11-3006757413ns5:ComputerEquipment2023-11-3006757413ns5:LandBuildingsns5:ShortLeaseholdAssets2024-11-3006757413ns5:FurnitureFittings2024-11-3006757413ns5:MotorVehicles2024-11-3006757413ns5:ComputerEquipment2024-11-3006757413ns5:LandBuildingsns5:ShortLeaseholdAssets2023-11-3006757413ns5:FurnitureFittings2023-11-3006757413ns5:MotorVehicles2023-11-3006757413ns5:ComputerEquipment2023-11-3006757413ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3006757413ns5:WithinOneYearns5:CurrentFinancialInstruments2023-11-3006757413ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2024-11-3006757413ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2023-11-30
REGISTERED NUMBER: 06757413 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 November 2024

for

Polyclinic Services Limited

Polyclinic Services Limited (Registered number: 06757413)






Contents of the Financial Statements
for the Year Ended 30 November 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Polyclinic Services Limited

Company Information
for the Year Ended 30 November 2024







DIRECTOR: S Patel





REGISTERED OFFICE: 39 Bromley Road
Catford
London
SE6 2TS





REGISTERED NUMBER: 06757413 (England and Wales)





ACCOUNTANTS: Kallis LLP
Chartered Certified Accountant
22 Westward Way
Harrow
Middlesex
HA3 0SE

Polyclinic Services Limited (Registered number: 06757413)

Balance Sheet
30 November 2024

30.11.24 30.11.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 327,558 349,503
Investment property 6 419,500 419,500
747,058 769,003

CURRENT ASSETS
Stocks 129,441 181,016
Debtors 7 2,184,121 1,655,996
Cash at bank and in hand 1,570,242 1,760,867
3,883,804 3,597,879
CREDITORS
Amounts falling due within one year 8 304,457 337,334
NET CURRENT ASSETS 3,579,347 3,260,545
TOTAL ASSETS LESS CURRENT
LIABILITIES

4,326,405

4,029,548

CREDITORS
Amounts falling due after more than one
year

9

542,779

542,779
NET ASSETS 3,783,626 3,486,769

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 3,783,526 3,486,669
SHAREHOLDERS' FUNDS 3,783,626 3,486,769

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Polyclinic Services Limited (Registered number: 06757413)

Balance Sheet - continued
30 November 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 28 August 2025 and were signed by:





S Patel - Director


Polyclinic Services Limited (Registered number: 06757413)

Notes to the Financial Statements
for the Year Ended 30 November 2024

1. STATUTORY INFORMATION

Polyclinic Services Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Purchased goodwill is initially recognised at cost. After recognition purchased goodwill is amortised over its expected useful life and measured at cost less accumulated amortisation.

Goodwill is considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceeds 10 years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Leasehold Improvement - 2% on cost
Fixtures and fittings - 25% on reducing balance
Motor vehicles - 25% on reducing balance
Computer equipment - 25% on reducing balance

Investment property
Investment property, which is property held to earn rentals and/or for capital appreciation, is initially
recognised at cost, which includes the purchase cost and any directly attributable expenditure.
Subsequently it is measured at fair value at the reporting end date. The surplus or deficit on revaluation is recognised in the profit and loss account.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Polyclinic Services Limited (Registered number: 06757413)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 18 (2023 - 17 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 December 2023
and 30 November 2024 300,000
AMORTISATION
At 1 December 2023
and 30 November 2024 300,000
NET BOOK VALUE
At 30 November 2024 -
At 30 November 2023 -

Polyclinic Services Limited (Registered number: 06757413)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

5. TANGIBLE FIXED ASSETS
Fixtures
Leasehold and Motor Computer
Improvement fittings vehicles equipment Totals
£    £    £    £    £   
COST
At 1 December 2023 402,505 69,989 87,495 18,899 578,888
Additions - 500 - 2,195 2,695
At 30 November 2024 402,505 70,489 87,495 21,094 581,583
DEPRECIATION
At 1 December 2023 116,665 59,434 38,280 15,006 229,385
Charge for year 8,050 2,764 12,304 1,522 24,640
At 30 November 2024 124,715 62,198 50,584 16,528 254,025
NET BOOK VALUE
At 30 November 2024 277,790 8,291 36,911 4,566 327,558
At 30 November 2023 285,840 10,555 49,215 3,893 349,503

6. INVESTMENT PROPERTY
Total
£   
FAIR VALUE
At 1 December 2023
and 30 November 2024 419,500
NET BOOK VALUE
At 30 November 2024 419,500
At 30 November 2023 419,500

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.24 30.11.23
£    £   
Trade debtors 187,927 203,506
Other debtors 1,973,000 1,403,000
VAT 20,384 45,588
Prepayments 2,810 3,902
2,184,121 1,655,996

Polyclinic Services Limited (Registered number: 06757413)

Notes to the Financial Statements - continued
for the Year Ended 30 November 2024

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.24 30.11.23
£    £   
Trade creditors 160,361 211,517
Tax 105,963 96,689
Directors Loan account 7,854 7,854
Accrued expenses 30,279 21,274
304,457 337,334

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
30.11.24 30.11.23
£    £   
Other loans more 5yrs non-inst 542,779 542,779

Amounts falling due in more than five years:

Repayable otherwise than by instalments
Other loans more 5yrs non-inst 542,779 542,779

10. RELATED PARTY DISCLOSURES

The company has taken advantage of the exemption available to group undertakings under FRS 102 Section 1A "Small Entities" by not disclosing transaction with wholly owned entities of the Polyclinic Holdings (2024) Limited.

Included within other debtors is an amount due from the following related parties:

Due from Bristol Pharma Limited £0 (2023: £200,000 ) a company in which Mr Sanjay Patel is a director and shareholder.

Due from PBS Enterprise Limited £328,000 (2023: £328,000 ) a company in which Mr Sanjay Patel is a shareholder.

Due from Suffolk Pharma Ltd £0 (2023: £550,000 ) a company in which Mr Sanjay Patel is a director and shareholder.

Due from Healthcare Limited £185,000 (2023: £325,000 ) a company in which Mr Sanjay Patel is a director .

Due from Saxmundham Pharma Limited £60,000 a company in which Mr Sanjay Patel is a shareholder.

All the above loans have no terms of repayments or interest attached to them.

11. ULTIMATE CONTROLLING PARTY

The company is a wholly owned subsidiary of Polyclinic Holdings (2024) Limited, a company registered in England and Wales. The ultimate controlling party of Polyclinic Holdings (2024) Limited is Mr Sanjay Patel.